Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY...
Tuesday, October 23, 2012, 3:06 PM ETIsis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles